Entities / Company
Standard BioTools Inc..
company in South San Francisco, United States
- Reports this week
- 0
- Active events
- 0
- Connections
- 22
What's happening
Gone quiet
No new reports in 90+ days-
Rallybio and Standard BioTools Inc. are currently involved in merger investigations.Some support1 report
-
Standard BioTools Inc. and Nyxoah are identified as competing small-cap medical companies in the market.Some support1 report
-
Standard BioTools Inc. is facing multiple corporate developments, including a merger announcement with Treeline Biosciences, a sale under review by Nuvei, and an investigation into a potential sale to Fox Corporation.Some support1 report
-
Standard BioTools acquired SomaLogic, retaining reagent rights for Illumina, following a strategic sale of SomaLogic to Illumina.Speculative1 report
-
Standard BioTools Inc. used LinkedIn for professional networking in July 2025.Some support1 report
-
Standard BioTools Inc. is conducting research in Singapore, led by John Chambers for the SG100K study.Some support1 report
-
Standard BioTools Inc. announced on August 13, 2025, that its revenue growth forecast exceeded the industry average.Some support1 report
No events began in the chosen period. Widen it, or reset.
Connections
The 1 strongest of 22, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Rallybio Mentioned together
Both companies are currently involved in merger investigations.
History
Events by the month they beganJuly 2026
2 eventsJune 2026
5 events- Standard BioTools Inc. is facing multiple corporate developments, including a merger announcement with Treeline Biosciences, a sale under review by Nuvei, and an investigation into a potential sale to Fox Corporation.
- Standard BioTools acquired SomaLogic, retaining reagent rights for Illumina, following a strategic sale of SomaLogic to Illumina.
- Standard BioTools Inc. used LinkedIn for professional networking in July 2025.
- Standard BioTools Inc. is conducting research in Singapore, led by John Chambers for the SG100K study.
- Standard BioTools Inc. announced on August 13, 2025, that its revenue growth forecast exceeded the industry average.